Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Suramin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY11 | Q96G91 | 9/20 | 1.00 |
| ▸ | RECQL | P46063 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 1.00 |
| ▸ | HPSE | Q9Y251 | 5/20 | 1.00 |
| ▸ | TIMP3 | P35625 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | PKM | P14618 | 4/20 | 1.00 |
| ▸ | P2RX1 | P51575 | 4/20 | 1.00 |
| ▸ | P2RX3 | P56373 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | USP2 | O75604 | 2/20 | 1.00 |
| ▸ | BRCA1 | P38398 | 2/20 | 1.00 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 1.00 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 1.00 |
| ▸ | ENPP3 | O14638 | 1/20 | 1.00 |
| ▸ | ENTPD3 | O75355 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Suramin SCHEMBL29357785 | 1.00 | P2RY11 (1.00) | P2RY11RECQLKMT2AHSD17B10TDP1 | |
| Suramin SCHEMBL30552218 | 1.00 | P2RY11 (1.00) | P2RY11RECQLKMT2AHSD17B10TDP1 | |
| Suramin SCHEMBL30312075 | 1.00 | P2RY11 (1.00) | P2RY11RECQLKMT2AHSD17B10TDP1 | |
| Suramin SCHEMBL29371906 | 1.00 | P2RY11 (1.00) | P2RY11RECQLKMT2AHSD17B10TDP1 | |
| SCHEMBL21686991 | 0.97 | P2RY11 (0.95) | P2RY11RECQLKMT2AHSD17B10TDP1 | |
| SCHEMBL20370854 | 0.95 | P2RY11 (0.90) | P2RY11RECQLKMT2AHSD17B10TDP1 | |
| SCHEMBL32686687 | 0.93 | P2RY11 (0.87) | P2RY11RECQLKMT2AHSD17B10TDP1 | |
| SCHEMBL16404704 | 0.93 | P2RY11 (0.86) | P2RY11RECQLKMT2AHSD17B10TDP1 | |
| SCHEMBL3358966 | 0.92 | RECQL (1.00) | P2RY11RECQLKMT2AHSD17B10TDP1 | |
| SCHEMBL30392305 | 0.92 | RECQL (1.00) | P2RY11RECQLKMT2AHSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 38854 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026106917-A1 | EDIBLE TRANSMUCOSAL DRUG DELIVERY METHOD USING AN INTERMEDIATE CAPSULE AS A TEMPORARY VESSEL | BioPhysics Pharma, Inc. (US) | 2026-05-21 | — | — | WO | claimed |
| EP-4735045-A2 | OXAZAPHOSPHORINE ANTIBODY DRUG CONJUGATES AND METHODS OF USE | La Life Products, LLC (US) | 2026-05-06 | — | — | EP | claimed |
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| EP-4732908-A2 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | Biomed Valley Discoveries, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| EP-3209683-B1 | FRAGMENTS OF SYNDECAN-2 HAVING ANTI-ANGIOGENIC ACTIVITY | SYNDECPHARMA LTD (GB) | 2026-04-29 | — | — | EP | claimed |
| US-20260109699-A1 | AZOLE DERIVATIVES AS SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2026-04-23 | — | — | US | claimed |
| US-12605345-B2 | Transdermal drug delivery system | BioPhysics Pharma, Inc. (US) | 2026-04-21 | — | — | US | claimed |
| EP-4714452-A1 | METHODS FOR TREATING SARS COV-2 INFECTIONS | Gilead Sciences, Inc. (US) | 2026-03-25 | — | — | EP | claimed |
| US-12582621-B2 | Compositions and methods for delivering pharmaceutical agents | Arizona Board of Regents on Behalf of the Universityof Arizona (US) | 2026-03-24 | — | — | US | claimed |
| EP-4426280-B1 | PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS | GURBA ALEXANDRE (CH) | 2026-03-18 | — | — | EP | claimed |
| WO-1989011277-A2 | PORPHYRIN AND PHTHALOCYANINE ANTIVIRAL COMPOSITIONS | GEORGIA STATE UNIVERSITY FOUNDATION, INC. (US) | 1989-11-30 | — | — | WO | claimed |
| EP-0342203-A1 | 2',3' DIDEOXYRIBOFURANOXIDE DERIVATIVES. | NYCOMED AS (NO) | 1989-11-23 | — | — | EP | claimed |
| EP-0263873-A4 | ANTI-PATHOGENIC BLOOD COLLECTION SYSTEM AND METHOD. | AL-SIOUFI HABIB | 1989-07-11 | — | — | EP | claimed |
| WO-1988007532-A1 | 2',3' DIDEOXYRIBOFURANOXIDE DERIVATIVES | NYCOMED A.S. (NO) | 1988-10-06 | — | — | WO | claimed |
| EP-0263873-A1 | ANTI-PATHOGENIC BLOOD COLLECTION SYSTEM AND METHOD | AL-SIOUFI, Habib (US) | 1988-04-20 | — | — | EP | claimed |
| US-4737521-A | Suramin sodium for use as an immunostimulant | BAYER AKTIENGESELLSCHAFT (DE) | 1988-04-12 | — | — | US | claimed |
| WO-1987006119-A1 | ANTI-PATHOGENIC BLOOD COLLECTION SYSTEM AND METHOD | AL SIOUFI HABIB | 1987-10-22 | — | — | WO | claimed |
| EP-0183352-A2 | Use of suramin for clinical treatment of infection with any of the members of the family of human-t-cell leukemia (htvl) viruses including lymphadenopathy virus (lav) | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce (US) | 1986-06-04 | — | — | EP | claimed |
| WO-1986002266-A1 | USE OF SURAMIN FOR CLINICAL TREATMENT OF INFECTION WITH ANY OF THE MEMBERS OF THE FAMILY OF HUMAN T-CELL LEUKEMIA (HTLV) VIRUSES INCLUDING LYMPHADENOPATHY VIRUS (LAV) | UNITED STATES OF AMERICA, REPRESENTED BY THE UNITE (US) | 1986-04-24 | — | — | WO | claimed |
| US-4218535-A | Determination of enzyme substrate concentration | BECKMAN INSTRUMENTS, INC. (US) | 1980-08-19 | — | — | US | claimed |